Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors.

Current pharmaceutical design - 1 Jan 2013

Voortman J, Harada T, Chang R P, Killian J K, Suuriniemi M, Smith W I, Meltzer P S, Lucchi M, Wang Y, Giaccone G

Abstract excerpt

BACKGROUND: We evaluated the mutation status of c-Met in small cell lung cancer (SCLC) and neuroendocrine tumors (NET), for which relatively limited therapeutic targets have been explored. MATERIALS AND METHODS: c-Met was re-sequenced using cell lines and clinical samples. For in vitro studies, DNA constructs containing a juxtamembrane domain (JMD) and tyrosine kinase domain (TKD) were generated. Detected...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neuroendocrine Tumors

Share to Piperazines

Share to Proto-Oncogene Proteins c-met

Share to Pyridones

Share to Small Cell Lung Carcinoma

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 22973954
PMCID: PMC7569720

Genes

MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors.PMID 22973954Read ↗

MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.Semantic proximity Read ↗

Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis.Semantic proximity Read ↗

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.Semantic proximity Read ↗

De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors.Semantic proximity Read ↗

MET Exon 14 Skipping Mutations: Essential Considerations for Current Management of Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies.Semantic proximity Read ↗

Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung CancerSemantic proximity Read ↗

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.Semantic proximity Read ↗

Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene.Semantic proximity Read ↗

MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.Semantic proximity Read ↗

Single-nucleotide polymorphism rs41736 located in MET was significantly associated with prognosis of small cell lung cancer patients.Semantic proximity Read ↗

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.